Compare Danaos Corporation (DAC) vs DexCom, Inc. (DXCM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaos Corporation vs DexCom, Inc. — how do they compare? Danaos Corporation trades at $138.94 (market cap $2.46B), while DexCom, Inc. trades at $90.53 (market cap $33.79B). The key difference: DexCom, Inc. is far larger — about 13.7× Danaos Corporation's market cap, and Danaos Corporation pays a 2.67% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DAC | DXCM | |
|---|---|---|
Market Cap | $2.46B | $33.79B |
Sector | Technology | Health |
52-Week High | $143.15 | $89.53 |
52-Week Low | $84.05 | $54.84 |
Enterprise Value | $2.44B | $33.24B |
Dividend Yield | 2.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DAC trades at $138.94, up 0.45% today, with a bullish technical signal supported by moving averages and oversold RSI indicators. The stock shows strong fundamentals with a low P/E of 4.57, robust net income margin of 51.26%, and consistent earnings beats in recent quarters. Recent news highlights record contracted revenue backlog and dividend declarations, reinforcing positive momentum.
Outlook remains favorable due to undervaluation and earnings strength, but risks include shipping market volatility and capital expenditure pressures. Analyst consensus is split evenly between Buy and Hold, indicating cautious optimism for continued growth amid sector-specific challenges.
DXCM trades at $90.23, up 2.94% today and near its 52-week high, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating EPS estimates with $0.70 versus $0.61 expected, and raised full-year guidance. Revenue growth remains robust at 13% year-over-year, supported by G7 system adoption and international expansion. Profit margins improved, with net income margin reaching 20.12% in 2025. Analyst sentiment is overwhelmingly positive, with 80% buy ratings.
The outlook for DXCM is favorable due to sustained demand for continuous glucose monitors and strategic initiatives like 'Road to 100'. Key risks include competitive pressures, regulatory scrutiny, and valuation multiples above industry averages. The stock's current price is slightly above the consensus target of $88.65, suggesting near-term consolidation may occur before further upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Danaos Corporation
Danaos is a leading international owner of containerships, providing seaborne transportation services globally. It charters its fleet of vessels to major shipping lines across Asia, Europe, and the Americas.
Read more on DAC →About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →
